Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Iovance Biotherapeutics Inc (IOVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,000,927
  • Shares Outstanding, K 123,514
  • Annual Sales, $ 0 K
  • Annual Income, $ -123,580 K
  • 60-Month Beta 1.97
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.43

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.29
  • Number of Estimates 8
  • High Estimate -0.18
  • Low Estimate -0.34
  • Prior Year -0.34
  • Growth Rate Est. (year over year) +14.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.15 +58.75%
on 05/13/19
16.58 -2.81%
on 05/16/19
+5.06 (+45.82%)
since 04/22/19
3-Month
9.21 +74.96%
on 03/25/19
16.58 -2.81%
on 05/16/19
+6.30 (+64.26%)
since 02/22/19
52-Week
7.26 +121.95%
on 12/21/18
18.25 -11.71%
on 08/31/18
-0.44 (-2.64%)
since 05/22/18

Most Recent Stories

More News
Implied Volatility Surging for Iovance Biotherapeutics (IOVA) Stock Options

Investors need to pay close attention to Iovance Biotherapeutics (IOVA) stock based on the movements in the options market lately.

IOVA : 16.25 (+0.31%)
First Week of July 19th Options Trading For Iovance Biotherapeutics (IOVA)

Investors in Iovance Biotherapeutics Inc saw new options begin trading this week, for the July 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IOVA options...

IOVA : 16.25 (+0.31%)
Thinking about buying stock in Aurora Cannabis, Applied Materials, Iovance Biotherapeutics, NVIDIA, or Under Armour?

InvestorsObserver issues critical PriceWatch Alerts for ACB, AMAT, IOVA, NVDA, and UAA.

AMAT : 40.34 (-2.25%)
NVDA : 152.10 (-1.91%)
ACBFF : 8.6900 (-12.80%)
IOVA : 16.25 (+0.31%)
UAA : 24.10 (+0.96%)
Iovance Biotherapeutics Announces Updates to Tumor Infiltrating Lymphocyte (TIL) Therapy Clinical Programs

Patients with advanced cervical cancer treated with LN-145 had an objective response rate of 44 percent

IOVA : 16.25 (+0.31%)
Iovance Biotherapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

- First patient dosed in pivotal Cohort 4 in study of lifileucel in advanced melanoma; regulatory submission planned for late 2020 -

IOVA : 16.25 (+0.31%)
Iovance Biotherapeutics to Participate in Upcoming Conferences in May

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the...

IOVA : 16.25 (+0.31%)
Iovance Biotherapeutics to Host First Quarter 2019 Financial Results Conference Call and Webcast on Tuesday, May 7, 2019

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it...

IOVA : 16.25 (+0.31%)
Iovance Biotherapeutics to Present New Data from Ongoing Studies of Tumor-Infiltrating Lymphocyte (TIL) Therapy at 2019 American Society of Clinical Oncology (ASCO) Meeting

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that new...

IOVA : 16.25 (+0.31%)
Iovance Biotherapeutics Announces Clinical Programs Update

- Design of cervical cancer study amended in anticipation for regulatory interactions -

IOVA : 16.25 (+0.31%)
Iovance Biotherapeutics Announces First Patient Dosed in Cohort 4 of Pivotal InnovaTIL-01 Study of Lifileucel in Metastatic Melanoma

- Patient dosing commenced in pivotal metastatic melanoma cohort -

IOVA : 16.25 (+0.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade IOVA with:

Business Summary

Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies...

See More

Key Turning Points

2nd Resistance Point 16.80
1st Resistance Point 16.50
Last Price 16.25
1st Support Level 15.77
2nd Support Level 15.34

See More

52-Week High 18.25
Last Price 16.25
Fibonacci 61.8% 14.05
Fibonacci 50% 12.76
Fibonacci 38.2% 11.46
52-Week Low 7.26

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar